Extended-release oral capsule of carbidopa-levodopa in parkinson disease

Jason Margolesky, Carlos Singer

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Motor fluctuations complicate the treatment of patients with Parkinson’s disease receiving levodopa. Extended-release carbidopa-levodopa has a pharmacokinetic profile that provides a more continuous levodopa serum concentration. Patients taking this formulation can expect longer duration of action and fewer doses per day, similar clinical improvement when compared to other levodopa formulations, and with a theoretically lower risk of developing motor fluctuations. Several studies, including three randomized control trials provide evidence for the efficacy, safety and tolerability of extended release carbidopa- levodopa in patients with both early and advanced Parkinson’s disease are reviewed here. Also provided is guidance for dosing of and conversion to extended release carbidopa-levodopa as well as a discussion of its place in the clinical practice.

Original languageEnglish (US)
JournalTherapeutic Advances in Neurological Disorders
Volume11
DOIs
StatePublished - Jan 1 2018

Fingerprint

Levodopa
Capsules
Parkinson Disease
Pharmacokinetics
Safety
Serum
levodopa drug combination carbidopa
Therapeutics

Keywords

  • Extended release carbidopa-levodopa
  • Parkinson’s disease
  • Rytary

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology

Cite this

Extended-release oral capsule of carbidopa-levodopa in parkinson disease. / Margolesky, Jason; Singer, Carlos.

In: Therapeutic Advances in Neurological Disorders, Vol. 11, 01.01.2018.

Research output: Contribution to journalReview article

@article{11d953207d22448c9d46f89f87a1cff3,
title = "Extended-release oral capsule of carbidopa-levodopa in parkinson disease",
abstract = "Motor fluctuations complicate the treatment of patients with Parkinson’s disease receiving levodopa. Extended-release carbidopa-levodopa has a pharmacokinetic profile that provides a more continuous levodopa serum concentration. Patients taking this formulation can expect longer duration of action and fewer doses per day, similar clinical improvement when compared to other levodopa formulations, and with a theoretically lower risk of developing motor fluctuations. Several studies, including three randomized control trials provide evidence for the efficacy, safety and tolerability of extended release carbidopa- levodopa in patients with both early and advanced Parkinson’s disease are reviewed here. Also provided is guidance for dosing of and conversion to extended release carbidopa-levodopa as well as a discussion of its place in the clinical practice.",
keywords = "Extended release carbidopa-levodopa, Parkinson’s disease, Rytary",
author = "Jason Margolesky and Carlos Singer",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/1756285617737728",
language = "English (US)",
volume = "11",
journal = "Therapeutic Advances in Neurological Disorders",
issn = "1756-2856",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Extended-release oral capsule of carbidopa-levodopa in parkinson disease

AU - Margolesky, Jason

AU - Singer, Carlos

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Motor fluctuations complicate the treatment of patients with Parkinson’s disease receiving levodopa. Extended-release carbidopa-levodopa has a pharmacokinetic profile that provides a more continuous levodopa serum concentration. Patients taking this formulation can expect longer duration of action and fewer doses per day, similar clinical improvement when compared to other levodopa formulations, and with a theoretically lower risk of developing motor fluctuations. Several studies, including three randomized control trials provide evidence for the efficacy, safety and tolerability of extended release carbidopa- levodopa in patients with both early and advanced Parkinson’s disease are reviewed here. Also provided is guidance for dosing of and conversion to extended release carbidopa-levodopa as well as a discussion of its place in the clinical practice.

AB - Motor fluctuations complicate the treatment of patients with Parkinson’s disease receiving levodopa. Extended-release carbidopa-levodopa has a pharmacokinetic profile that provides a more continuous levodopa serum concentration. Patients taking this formulation can expect longer duration of action and fewer doses per day, similar clinical improvement when compared to other levodopa formulations, and with a theoretically lower risk of developing motor fluctuations. Several studies, including three randomized control trials provide evidence for the efficacy, safety and tolerability of extended release carbidopa- levodopa in patients with both early and advanced Parkinson’s disease are reviewed here. Also provided is guidance for dosing of and conversion to extended release carbidopa-levodopa as well as a discussion of its place in the clinical practice.

KW - Extended release carbidopa-levodopa

KW - Parkinson’s disease

KW - Rytary

UR - http://www.scopus.com/inward/record.url?scp=85041387699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041387699&partnerID=8YFLogxK

U2 - 10.1177/1756285617737728

DO - 10.1177/1756285617737728

M3 - Review article

AN - SCOPUS:85041387699

VL - 11

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

SN - 1756-2856

ER -